Selected results of a post-registration observational study on the clinical efficacy and tolerability of Bimicombi Antiglau ECO and Brim Antiglau ECO in different stages of primary open-angle glaucoma in real-world clinical practice (Brim Bimicombi Antiglau Real World Ophthalmology, BRAWO)
Authors:   Mandryka Central Military Clinical Hospital, Moscow, Russian Federation, Kuroyedov A.V. ,   Pirogov Russian National Research Medical University, Moscow, Russian Federation, Kosakovskaya M.V. ,   Pirogov Russian National Research Medical University, Moscow, Russian Federation,   JSC "Group of Companies MEDSI", Moscow, Russian Federation, Gapon'ko O.V. ,   Mandryka Central Military Clinical Hospital, Moscow, Russian Federation,   Pirogov Russian National Research Medical University, Moscow, Russian Federation, Gorodnichiy V.V. ,   Mandryka Central Military Clinical Hospital, Moscow, Russian Federation, Lovpache D.N. ,   Pirogov Russian National Research Medical University, Moscow, Russian Federation,   Ophthalmological Clinic “3Z”, Moscow, Russian Federation, Bulakh I.A. ,   LLC Medical Center "Ivastramed", Ivanovo, Russian Federation
Published: August 2023

Aim: to assess the clinical efficacy and tolerability of bimatoprost/timolol (Bimicombi Antiglau ECO) and brimonidine (Brim Antiglau ECO) in different stages of primary open-angle glaucoma (POAG) compared with prior therapy. Patients and Methods: data from 1036 patients were included in the final protocol of the multicenter combined scientific and clinical study. All patients were diagnosed with POAG or were glaucoma suspects (GS) with ocular hypertension (OHT). All patients underwent a complex eye examination. Treatment with the drugs studied should have lasted 2 to 4 months. Treatment choice resulted from the lack of efficacy, ineffectiveness, or intolerance of prior therapies. The control study was conducted once not less than a month after inclusion in the study. Results: POAG (any stage) was diagnosed in 982 patients (94.8%), and GS with OHT were 54 patients (5.2%). Changing treatment regimen (in a planned manner) prevented tachyphylaxis and tolerance to previously prescribed drugs, which was established by IOP measurements (a 20% reduction in IOP compared with prior data). If the regimen was changed for any reason (overall, 6 reasons were analyzed), three most common reasons were poor clinical efficacy (36.6%), discomfort (26.6%), and poor tolerability (23.9%). Prescription of preservative-free IOP-lowering medications (eye drops studied) for 1 month after the washout period significantly (by 19 times) reduced the number of these complaints. Preservative-free medications significantly increase the maximum satisfaction with prescribed treatment regimens (Likert score 4.61 of 5) and largely meet the expectations of doctors in terms of drug efficacy and tolerability (Likert score 4.67 of 5). Conclusion: preservative-free IOP-lowering medications (eye drops studied) are effective and well tolerated. KEYWORDS: glaucoma therapy, efficacy, tolerability, bimatoprost/timolol, brimonidine, primary open-angle glaucoma, real-world clinical practice, BRAWO. FOR CITATION: Kuroyedov A.V., Kosakovskaya M.V., Gapon'ko O.V., Gorodnichiy V.V., Lovpache D.N., Bulakh I.A. Selected results of a post- registration observational study on the clinical efficacy and tolerability of Bimicombi Antiglau ECO and Brim Antiglau ECO in different stages of primary open-angle glaucoma in real-world clinical practice (Brim Bimicombi Antiglau Real World Ophthalmology, BRAWO). Russian Journal of Clinical Ophthalmology. 2023;23(3):129–135 (in Russ.). DOI: 10.32364/2311-7729-2023-23-3-4.